Fink Jeffrey Arvin 4
4 · Lipocine Inc. · Filed Jan 2, 2018
Insider Transaction Report
Form 4
Lipocine Inc.LPCN
Fink Jeffrey Arvin
Director
Transactions
- Exercise/Conversion
Common Stock
2017-12-29+1,875→ 1,875 total - Sale
Common stock
2017-12-29$3.47/sh−938$3,258→ 937 total - Exercise/Conversion
Restricted Stock Unit
2017-12-29−1,875→ 5,625 totalExercise: $0.00From: 2017-12-29Exp: 2027-01-25→ Common stock (1,875 underlying)
Footnotes (4)
- [F1]Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4).
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F3]Represents the weighted average price of shares sold at a price that ranged from $3.43-$3.54.
- [F4]Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021.